o2h ChaiTime Webinar: Trump’s Most-Favored-Nation Drug Pricing is Rewiring Traditional R&D Model
Join us for the upcoming o2h ChaiTime Webinar, where our expert panellists will discuss how MFN pricing could reshape R&D strategies, operations, decision-making for biotech and pharma.
The biopharma landscape is shifting fast, driven by evolving pricing policies, geopolitical trade tensions, and mounting pressure to optimise R&D investment. With the recent push toward nation-based drug pricing, global companies are being forced to rethink not just pricing models, but where and how they innovate.